1
|
Laureano AF, Vigato AA, Puzer L, de Araujo DR. Recombinant scFv-Fc Anti-kallikrein 7 Antibody-Loaded Thermosensitive Hydrogels Against Skin Desquamation Disorders. ACS APPLIED BIO MATERIALS 2024; 7:4486-4496. [PMID: 38886921 PMCID: PMC11253099 DOI: 10.1021/acsabm.4c00371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2024] [Revised: 06/01/2024] [Accepted: 06/04/2024] [Indexed: 06/20/2024]
Abstract
Human tissue kallikrein-related peptidase 7 (KLK7) is a serine protease implicated in the physiology of skin desquamation, and its uncontrolled activity can lead to chronic diseases such as psoriasis, atopic dermatitis, and Netherton syndrome. For this reason, kallikrein 7 has been identified as a potential therapeutic target. This work aimed to evaluate Pluronic (PL) hydrogels as topical carriers of four specific scFv-Fc antibodies to inhibit KLK7. The hydrogels comprised PL F127 (30% w/v) alone and a binary F127/P123 (28-2% w/v) system. Each formulation was loaded with 1 μg/mL of each antibody and characterized by physicochemical and pharmaceutical techniques, considering antibody-micelle interactions and hydrogel behavior as smart delivery systems. Results showed that the antibodies were successfully loaded into the PL-based systems, and the sol-gel transition temperature was shifted to high values after the P123 addition. The antibodies released from the gels preserved their rheological properties (G' > G'', 35- to 41-fold) and inhibitory activity against KLK7, even after 24 h. This work presented potential agents targeting KLK7 that may provide strategies for treating skin abnormalities.
Collapse
Affiliation(s)
- Ana Flávia
Santarine Laureano
- Department
of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital & Harvard Medical School, CNY149 13th Street, Charlestown, Boston, Massachusetts 02129, United States
- Centro
de Ciências Naturais e Humanas, Universidade
Federal do ABC, Al. da Universidade, s/n-Anchieta, São
Bernardo do Campo, SP 09606-045, Brazil
| | - Aryane Alves Vigato
- Department
of Biomedical Science (BMV), Faculty of Health and Society, Malmö University, Malmö 20506, Sweden
- Biofilms−Research
Center for Biointerfaces, Malmö University, Malmö 20506, Sweden
| | - Luciano Puzer
- Centro
de Ciências Naturais e Humanas, Universidade
Federal do ABC, Al. da Universidade, s/n-Anchieta, São
Bernardo do Campo, SP 09606-045, Brazil
| | - Daniele Ribeiro de Araujo
- Centro
de Ciências Naturais e Humanas, Universidade
Federal do ABC, Av. dos
Estados, 5001, Bloco A, Torre 3, Santo André, SP 09210-580, Brazil
- Departamento
de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu, 862, Vila Clementino, Sao Paulo, SP 04023-062, Brazil
| |
Collapse
|
2
|
Hernandez-Rocha JV, Vásquez-Morales SG. The Potential of Magnolia spp. in the Production of Alternative Pest Control Substances. Molecules 2023; 28:4681. [PMID: 37375236 PMCID: PMC10303668 DOI: 10.3390/molecules28124681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 06/07/2023] [Accepted: 06/08/2023] [Indexed: 06/29/2023] Open
Abstract
The irrational use of synthetic pesticides in agriculture has had negative impacts on ecosystems and contributed to environmental pollution. Botanical pesticides offer a clean biotechnological alternative to meet the agricultural challenges posed by pests and arthropods. This article proposes the use of fruit structures (fruit, peel, seed, and sarcotesta) of several Magnolia species as biopesticides. The potential of extracts, essential oils, and secondary metabolites of these structures for pest control is described. From 11 Magnolia species, 277 natural compounds were obtained, 68.7% of which were terpenoids, phenolic compounds, and alkaloids. Finally, the importance of a correct management of Magnolia species to ensure their sustainable use and conservation is stressed.
Collapse
Affiliation(s)
| | - Suria Gisela Vásquez-Morales
- Department of Biology, Division of Natural and Exact Sciences, University of Guanajuato, Guanajuato 36050, Mexico
| |
Collapse
|
3
|
Kim JM, Seo SW, Han DG, Yun H, Yoon IS. Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo. Pharmaceutics 2021; 13:pharmaceutics13060782. [PMID: 34071139 PMCID: PMC8224802 DOI: 10.3390/pharmaceutics13060782] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 05/18/2021] [Accepted: 05/20/2021] [Indexed: 02/03/2023] Open
Abstract
Repaglinide (RPG), a rapid-acting meglitinide analog, is an oral hypoglycemic agent for patients with type 2 diabetes mellitus. Quercetin (QCT) is a well-known antioxidant and antidiabetic flavonoid that has been used as an important ingredient in many functional foods and complementary medicines. This study aimed to comprehensively investigate the effects of QCT on the metabolism of RPG and its underlying mechanisms. The mean (range) IC50 of QCT on the microsomal metabolism of RPG was estimated to be 16.7 (13.0–18.6) μM in the rat liver microsome (RLM) and 3.0 (1.53–5.44) μM in the human liver microsome (HLM). The type of inhibition exhibited by QCT on RPG metabolism was determined to be a mixed inhibition with a Ki of 72.0 μM in RLM and 24.2 μM in HLM as obtained through relevant graphical and enzyme inhibition model-based analyses. Furthermore, the area under the plasma concentration versus time curve (AUC) and peak plasma concentration (Cmax) of RPG administered intravenously and orally in rats were significantly increased by 1.83- and 1.88-fold, respectively, after concurrent administration with QCT. As the protein binding and blood distribution of RPG were observed to be unaltered by QCT, it is plausible that the hepatic first-pass and systemic metabolism of RPG could have been inhibited by QCT, resulting in the increased systemic exposure (AUC and Cmax) of RPG. These results suggest that there is a possibility that clinically significant pharmacokinetic interactions between QCT and RPG could occur, depending on the extent and duration of QCT intake from foods and dietary supplements.
Collapse
Affiliation(s)
| | | | | | - Hwayoung Yun
- Correspondence: (H.Y.); (I.-S.Y.); Tel.: +82-51-510-2810 (H.Y.); +82-51-510-2806 (I.-S.Y.)
| | - In-Soo Yoon
- Correspondence: (H.Y.); (I.-S.Y.); Tel.: +82-51-510-2810 (H.Y.); +82-51-510-2806 (I.-S.Y.)
| |
Collapse
|
4
|
Menezes JCJMDS, Diederich MF. Bioactivity of natural biflavonoids in metabolism-related disease and cancer therapies. Pharmacol Res 2021; 167:105525. [PMID: 33667686 DOI: 10.1016/j.phrs.2021.105525] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 02/06/2021] [Accepted: 02/27/2021] [Indexed: 12/17/2022]
Abstract
Natural biflavonoids, such as amentoflavone, bilobetin, ginkgetin, isoginkgetin, taiwaniaflavone, morelloflavone, delicaflavone, hinokiflavone, and other derivatives (~ 40 biflavonoids), are isolated from Selaginella sp., Ginkgo biloba, Garcinia sp., and several other species of plants. They are able to exert therapeutic benefits by regulating several proteins/enzymes (PPAR-γ, CCAAT/enhancer-binding protein α [C/EBPα], STAT5, pancreatic lipase, PTP1B, fatty acid synthase, α-glucosidase [AG]) and insulin signaling pathways (via PI3K-AKT), which are linked to metabolism, cell growth, and cell survival mechanisms. Deregulated insulin signaling can cause complications of obesity and diabetes, which can lead to cognitive disorders such as Alzheimer's, Parkinson's, and dementia; therefore, the therapeutic benefits of these biflavones in these areas are highlighted. Since biflavonoids have shown potential to regulate metabolism, growth- and survival-related protein/enzymes, their relation to tumor growth and metastasis of cancer associated with angiogenesis are highlighted. The translational role of biflavones in cancer with respect to the inhibition of metabolism-related processes/pathways, enzymes, or proteins, such as STAT3/SHP-1/PTEN, kinesins, tissue kallikreins, aromatase, estrogen, protein modifiers, antioxidant, autophagy, and apoptosis induction mechanisms, are discussed. Finally, considering their observed bioactivity potential, oral bioavailability studies of biflavones and related clinical trials are outlined.
Collapse
Affiliation(s)
- José C J M D S Menezes
- Faculty of Pharmaceutical Sciences, Nagasaki International University, 2825-7 Huis Ten Bosch, Sasebo, Nagasaki 859-3298, Japan
| | - Marc F Diederich
- Department of Pharmacy, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, South Korea.
| |
Collapse
|
5
|
Laureano AFS, Zani MB, Sant'Ana AM, Tognato RC, Lombello CB, do Nascimento MHM, Helmsing S, Fühner V, Hust M, Puzer L. Generation of recombinant antibodies against human tissue kallikrein 7 to treat skin diseases. Bioorg Med Chem Lett 2020; 30:127626. [PMID: 33096161 DOI: 10.1016/j.bmcl.2020.127626] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Revised: 10/09/2020] [Accepted: 10/14/2020] [Indexed: 12/25/2022]
Abstract
Human tissue kallikreins (KLKs) constitute a family of 15 serine proteases that are distributed in various tissues and implicated in several pathological disorders. KLK7 is an unusual serine protease that presents both trypsin-like and chymotrypsin-like specificity and appears to be upregulated in pathologies that are related to skin desquamation processes, such as atopic dermatitis, psoriasis and Netherton syndrome. In recent years, various groups have worked to develop specific inhibitors for this enzyme, as KLK7 represents a potential target for new therapeutic procedures for diseases related to skin desquamation processes. In this work, we selected nine different single-chain variable fragment antibodies (scFv) from a human naïve phage display library and characterized their inhibitory activities against KLK7. The scFv with the lowest IC50 against KLK7 was affinity maturated, which resulted in the generation of four new scFv-specific antibodies for the target protease. These new antibodies were expressed in the scFv-Fc format in HEK293-6E cells, and the characterization of their inhibitory activities against KLK7 showed that three of them presented IC50 values lower than that of the original antibody. The cytotoxicity analysis of these recombinant antibodies demonstrated that they can be safely used in a cellular model. In conclusion, our research showed that in our case, a phage-display methodology in combination with enzymology assays can be a very suitable tool for the development of inhibitors for KLKs, suggesting a new strategy to identify therapeutic protease inhibitors for diseases related to uncontrolled kallikrein activity.
Collapse
Affiliation(s)
- Ana Flávia S Laureano
- Universidade Federal do ABC - Centro de Ciências Naturais e Humanas, São Bernardo do Campo, São Paulo, Brazil
| | - Marcelo B Zani
- Universidade Federal do ABC - Centro de Ciências Naturais e Humanas, São Bernardo do Campo, São Paulo, Brazil
| | - Aquiles M Sant'Ana
- Universidade Federal do ABC - Centro de Ciências Naturais e Humanas, São Bernardo do Campo, São Paulo, Brazil
| | - Rafael C Tognato
- Universidade Federal do ABC - Centro de Ciências Naturais e Humanas, São Bernardo do Campo, São Paulo, Brazil
| | - Christiane B Lombello
- Universidade Federal do ABC - Centro de Engenharia, Modelagem e Ciências Sociais aplicadas, São Bernardo do Campo, São Paulo, Brazil
| | - Mônica Helena M do Nascimento
- Universidade Federal do ABC - Centro de Engenharia, Modelagem e Ciências Sociais aplicadas, São Bernardo do Campo, São Paulo, Brazil
| | - Saskia Helmsing
- Technische Universität Braunschweig - Abteilung Biotechnologie, Institut für Biochemie, Biotechnologie und Bioinformatik, Braunschweig, Germany
| | - Viola Fühner
- Technische Universität Braunschweig - Abteilung Biotechnologie, Institut für Biochemie, Biotechnologie und Bioinformatik, Braunschweig, Germany
| | - Michael Hust
- Technische Universität Braunschweig - Abteilung Biotechnologie, Institut für Biochemie, Biotechnologie und Bioinformatik, Braunschweig, Germany
| | - Luciano Puzer
- Universidade Federal do ABC - Centro de Ciências Naturais e Humanas, São Bernardo do Campo, São Paulo, Brazil.
| |
Collapse
|
6
|
Di Paolo CT, Diamandis EP, Prassas I. The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets. Crit Rev Clin Lab Sci 2020; 58:1-16. [PMID: 32568598 DOI: 10.1080/10408363.2020.1775171] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The skin is a vital organ of the human body, serving numerous protective and functional roles that are essential for survival. Residing in the epidermis are various epidermal proteases responsible for the establishment and regulation of barrier function. The human tissue kallikrein-related peptidase family conserves homeostasis of the skin barrier through their roles in desquamation, antimicrobial defense, innate immune response, and barrier maintenance. The activity of kallikreins is tightly regulated and dysregulation of kallikrein activity is seen to contribute to the formation of several inflammatory skin disorders. This review highlights the roles of kallikreins in skin homeostasis and pathologies. Due to their part in these skin disorders, inhibitors of the skin kallikreins have become attractive therapeutics. Over the past few years, both natural and synthetic inhibitors of several kallikreins have been identified and are undergoing further development as treatments to restore compromised barrier function. This review summarizes the kallikrein inhibitors under development for this purpose. These inhibitors remain promising therapeutics in cases of severe skin inflammation not well managed by current therapies.
Collapse
Affiliation(s)
- Caitlin T Di Paolo
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
| | - Eleftherios P Diamandis
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.,Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.,Department of Clinical Biochemistry, University Health Network, Toronto, Canada
| | - Ioannis Prassas
- Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada
| |
Collapse
|
7
|
Moradi A, Srinivasan S, Clements J, Batra J. Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment. Cancer Metastasis Rev 2020; 38:333-346. [PMID: 31659564 DOI: 10.1007/s10555-019-09815-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The prostate-specific antigen (PSA) blood test is the accepted biomarker of tumor recurrence. PSA levels in serum correlate with disease progression, though its diagnostic accuracy is questionable. As a result, significant progress has been made in developing modified PSA tests such as PSA velocity, PSA density, 4Kscore, PSA glycoprofiling, Prostate Health Index, and the STHLM3 test. PSA, a serine protease, is secreted from the epithelial cells of the prostate. PSA has been suggested as a molecular target for prostate cancer therapy due to the fact that it is not only active in prostate tissue but also has a pivotal role on prostate cancer signaling pathways including proliferation, invasion, metastasis, angiogenesis, apoptosis, immune response, and tumor microenvironment regulation. Here, we summarize the current standing of PSA in prostate cancer progression as well as its utility in prostate cancer therapeutic approaches with an emphasis on the role of PSA in the tumor microenvironment.
Collapse
Affiliation(s)
- Afshin Moradi
- School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.,Translational Research Institute, Queensland University of Technology, Brisbane, Australia
| | - Srilakshmi Srinivasan
- School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.,Translational Research Institute, Queensland University of Technology, Brisbane, Australia
| | - Judith Clements
- School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.,Translational Research Institute, Queensland University of Technology, Brisbane, Australia
| | - Jyotsna Batra
- School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia. .,Translational Research Institute, Queensland University of Technology, Brisbane, Australia.
| |
Collapse
|
8
|
de Souza AS, Pacheco BDC, Pinheiro S, Muri EMF, Dias LRS, Lima CHS, Garrett R, de Moraes MBM, de Souza BEG, Puzer L. 3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7. Bioorg Med Chem Lett 2019; 29:1094-1098. [PMID: 30833107 DOI: 10.1016/j.bmcl.2019.02.031] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Revised: 02/25/2019] [Accepted: 02/26/2019] [Indexed: 12/30/2022]
Abstract
Human kallikreins 5 and 7 (KLK5 and KLK7) exhibit trypsin- and chymotrypsin-like activities and are involved in pathologies related to skin desquamation process. A series of new 3-acyltetramic acids were developed as a novel class of inhibitors of KLK5, KLK7 and trypsin enzymes. The nature and length of the acyl chain is crucial to the KLK5, KLK7 and trypsin inhibition activities, and the most potent compounds (but not the most selective) 2b, 2c and 2g showed low micromolar IC50 values. While very few of the compounds were selective for KLK5, the selective inhibition of trypsin against chymotrypsin was achieved. Our molecular modelling studies revealed that the double bond in 2g provided the best fit in the binding site of KLK5, while the hydrogen bonding interactions modulated the best fit of 2c in the binding site of KLK7 due to the hydrophobicity of the cavity.
Collapse
Affiliation(s)
- Acácio S de Souza
- Instituto de Química, Universidade Federal Fluminense, Outeiro de S. João Batista s/n, Centro, 24020-141 Niterói, RJ, Brazil
| | - Barbara D C Pacheco
- Instituto de Química, Universidade Federal Fluminense, Outeiro de S. João Batista s/n, Centro, 24020-141 Niterói, RJ, Brazil
| | - Sergio Pinheiro
- Instituto de Química, Universidade Federal Fluminense, Outeiro de S. João Batista s/n, Centro, 24020-141 Niterói, RJ, Brazil.
| | - Estela M F Muri
- Departamento de Tecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, RJ, Brazil.
| | - Luiza R S Dias
- Departamento de Tecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, RJ, Brazil
| | - Camilo H S Lima
- Departamento de Tecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal Fluminense, Niterói, RJ, Brazil
| | - Rafael Garrett
- Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Mariana B M de Moraes
- Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
| | - Bruno E G de Souza
- Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Santo André, SP, Brazil
| | - Luciano Puzer
- Centro de Ciências Naturais e Humanas, Universidade Federal do ABC, Santo André, SP, Brazil
| |
Collapse
|
9
|
Loessner D, Goettig P, Preis S, Felber J, Bronger H, Clements JA, Dorn J, Magdolen V. Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer. Expert Opin Ther Targets 2018; 22:745-763. [PMID: 30114962 DOI: 10.1080/14728222.2018.1512587] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Aberrant levels of kallikrein-related peptidases (KLK1-15) have been linked to cancer cell proliferation, invasion and metastasis. In ovarian cancer, the KLK proteolytic network has a crucial role in the tissue and tumor microenvironment. Publically available ovarian cancer genome and expression data from multiple patient cohorts show an upregulation of most KLKs. Areas covered: Here, we review the expression levels of all 15 members of this family in normal and ovarian cancer tissues, categorizing them into highly and moderately or weakly expressed KLKs, and their association with patient prognosis and survival. We summarize their tumor-biological functions determined in cell-based assays and xenograft models, further highlighting their suitability as cancer biomarkers and attractive candidates for drug development. Finally, we discuss some different pharmaceutical approaches, including peptide-based and small molecule inhibitors, cyclic peptides, depsipeptides, engineered natural inhibitors, antibodies, RNA/DNA-based aptamers, prodrugs, miRNA and siRNA. Expert opinion: In light of the results from clinical and tumor-biological studies, together with the available pharmaceutical tools, we suggest KLK4, KLK5, KLK6 and possibly KLK7 as preferred targets for inhibition in ovarian cancer.
Collapse
Affiliation(s)
- Daniela Loessner
- a Barts Cancer Institute , Queen Mary University of London , London , UK.,b Institute of Health and Biomedical Innovation , Queensland University of Technology (QUT) , Brisbane , Australia
| | - Peter Goettig
- c Department of Biosciences , University of Salzburg , Salzburg , Austria
| | - Sarah Preis
- d Department of Obstetrics and Gynecology , Technical University of Munich , Munich , Germany
| | - Johanna Felber
- d Department of Obstetrics and Gynecology , Technical University of Munich , Munich , Germany
| | - Holger Bronger
- d Department of Obstetrics and Gynecology , Technical University of Munich , Munich , Germany
| | - Judith A Clements
- b Institute of Health and Biomedical Innovation , Queensland University of Technology (QUT) , Brisbane , Australia.,e Australian Prostate Cancer Research Centre - Queensland , Queensland University of Technology (QUT), Translational Research Institute , Brisbane , Australia
| | - Julia Dorn
- d Department of Obstetrics and Gynecology , Technical University of Munich , Munich , Germany
| | - Viktor Magdolen
- d Department of Obstetrics and Gynecology , Technical University of Munich , Munich , Germany
| |
Collapse
|
10
|
Masurier N, Arama DP, El Amri C, Lisowski V. Inhibitors of kallikrein-related peptidases: An overview. Med Res Rev 2017; 38:655-683. [DOI: 10.1002/med.21451] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Revised: 04/24/2017] [Accepted: 05/16/2017] [Indexed: 12/11/2022]
Affiliation(s)
- Nicolas Masurier
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS; Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques; Montpellier Cedex France
| | - Dominique P. Arama
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS; Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques; Montpellier Cedex France
| | - Chahrazade El Amri
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256; Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology; Paris France
| | - Vincent Lisowski
- Institut des Biomolécules Max Mousseron, UMR 5247, CNRS; Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques; Montpellier Cedex France
| |
Collapse
|
11
|
Barros TG, Santos JA, de Souza BE, Sodero ACR, de Souza AM, da Silva DP, Rodrigues CR, Pinheiro S, Dias LR, Abrahim-Vieira B, Puzer L, Muri EM. Discovery of a new isomannide-based peptidomimetic synthetized by Ugi multicomponent reaction as human tissue kallikrein 1 inhibitor. Bioorg Med Chem Lett 2017; 27:314-318. [DOI: 10.1016/j.bmcl.2016.11.051] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Accepted: 11/17/2016] [Indexed: 01/17/2023]
|